EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study

Yanling Ma, Hui Xia, Xueyun Tan, Siwei Song, Minglei Li, Juanjuan Xu, Feng Wu, Yaqi Cao, Mengjia Yi, Sufei Wang, Yang Jin iD

Technology in Cancer Research & Treatment · 2026-07 · 25

DOI: 10.1177/15330338261456855 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 03.07.2026. Verfasst von Yanling Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, NHC Key Laboratory of P…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Crown Ethers, Bone Neoplasms, Lung Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hubei Province key research and development project, Ministry of Science and Technology of the People’s Republic of China, National NaturalScience Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Clinical prediction models for response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung cancer (NSCLC) with bone metastasis (BoM) and EGFR mutations are lacking. This study evaluated predictors of response to the EGFR-TKI icotinib in patients with NSCLC and BoM.

Methods

We retrospectively analysed patients with EGFR-mutated NSCLC and BoM treated with icotinib at Wuhan Union Hospital. Least absolute shrinkage and selection operator and multivariate Cox regression analyses identified independent predictors of progression-free survival (PFS). A prognostic nomogram was developed, and its effectiveness was assessed using receiver operating characteristic (ROC) curves, a decision curve analysis (DCA), and calibration curves.

Results

Among 194 patients (106 with and 88 without BoM), median PFS in the BoM group was 9.8 months, with a 35.8% overall response rate, and 66.0% disease control rate. In univariate and multivariate Cox regression analyses, BoM was an independent predictor of PFS in the overall cohort (hazard ratio [HR], 2.12; 95% confidence interval [CI], 1.34–3.07; P < 0.001). In the BoM subgroup, albumin (HR: 0.36; 95% CI: 0.21–0.62; P < 0.001), lactate dehydrogenase (LDH) (HR: 1.99; 95% CI: 1.21–3.28; P = 0.007), and the platelet–lymphocyte ratio (PLR) (HR: 1.85; 95% CI: 1.05–3.25; P = 0.033) were independently associated with PFS. A nomogram predicting 3-, 6-, and 12-month PFS achieved time-dependent areas under the ROC curve of 0.765, 0.743, and 0.724, respectively. Calibration plots and DCA demonstrated acceptable performance and potential clinical relevance.

Conclusions

Albumin, LDH, and PLR predict PFS in EGFR-mutated NSCLC with BoM treated with icotinib. The proposed nomogram may assist in preliminary risk stratification in this specific population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCrown EthersBone NeoplasmsLung NeoplasmsMutationQuinazolinesAntineoplastic AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedErbB ReceptorsAgedPrognosisNomogramsProtein Kinase InhibitorsAdultAged, 80 and overROC CurveTreatment Outcome

Stichwörter der Autor:innen

bone metastasesnomogramnon-small cell lung cancerprogression-free survivalsurvival prediction modeltyrosine kinase inhibitors

Substanzen

Crown EthersicotinibErbB ReceptorsQuinazolinesProtein Kinase InhibitorsEGFR protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Hubei Province Clinical Research Center for Major Respiratory Diseases, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong Un…
  • Hubei Province Key Laboratory of Biological Targeted Therapy, MOE Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Province Engineering Research Center for Tumor-Targeted Biochemotherapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Yang Jin

Förderung

  • Hubei Province key research and development project
  • Ministry of Science and Technology of the People’s Republic of China
  • National NaturalScience Foundation of China

Zitieren

APA

Ma, Y., Xia, H., Tan, X., Song, S., Li, M., Xu, J., Wu, F., Cao, Y., Yi, M., Wang, S., & Jin, Y. (2026). Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261456855

Vancouver

Ma Y, Xia H, Tan X, Song S, Li M, Xu J, et al. Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261456855

BibTeX
@article{Ma2026,
  author = {Ma, Yanling and Xia, Hui and Tan, Xueyun and Song, Siwei and Li, Minglei and Xu, Juanjuan and Wu, Feng and Cao, Yaqi and Yi, Mengjia and Wang, Sufei and Jin, Yang},
  title = {Survival Prediction in Patients With Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer With Bone Metastases Receiving Icotinib Therapy: A Retrospective Observational Study},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  volume = {25},
  doi = {10.1177/15330338261456855}
}
Kostenlos starten →